BrokeInvest
2021-08-13

$Trillium Therapeutics(TRIL)$operating planis on track. Focus is on strong execution

to ensure a robust flow of new data starting in 4Q 2021 and 2022. Holding $265m cash position. Trillium’s position as a leading CD47 company makes it a buy at $6.10

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment